Role of Hydromorphone in Palliative Pain Management

Indications and Place in Therapy

Hydromorphone is classified as a WHO Level III analgesic (strong opioid) for moderate to severe pain, according to the World Health Organization 2, 3
Hydromorphone is available in both immediate-release and modified-release formulations for oral administration, making it versatile for different pain management needs, as recommended by the American Society of Clinical Oncology 1, 4
In palliative care settings, hydromorphone can be used as a first-line alternative to morphine when morphine is not tolerated or contraindicated, as suggested by the European Society for Medical Oncology 1, 2

Hydromorphone is extensively metabolized via glucuronidation in the liver, with minimal unchanged drug excreted in urine, making it potentially safer in patients with renal impairment compared to morphine, according to the National Comprehensive Cancer Network 1

Oral administration is the preferred route in palliative care when possible, as recommended by the American Academy of Hospice and Palliative Medicine 1, 2
For severe pain requiring urgent relief, parenteral hydromorphone (subcutaneous or intravenous) can be administered, as suggested by the European Association for Palliative Care 1, 3
When converting from oral to parenteral hydromorphone, the dose should be divided by 2-3 to get an equianalgesic effect, according to the American Society of Clinical Oncology 1
For breakthrough pain, rescue doses are typically calculated as 10-15% of the total daily dose, as recommended by the National Comprehensive Cancer Network 4

Hydromorphone has a relative potency ratio of approximately 5-7.5 times that of oral morphine, according to the World Health Organization 5
In palliative care settings, hydromorphone is considered equally effective to morphine for pain control, as suggested by the European Society for Medical Oncology 1, 2

Hydromorphone may be particularly useful in patients with renal impairment, poor tolerance to morphine, or need for rapid pain control in severe pain crises, as recommended by the American Academy of Hospice and Palliative Medicine 1, 2

Start with immediate-release formulations for dose titration, then consider modified-release formulations for maintenance therapy, as suggested by the European Association for Palliative Care 1, 2
Regular reassessment of pain control and side effects is essential, according to the National Comprehensive Cancer Network 8, 2
Consider opioid rotation to hydromorphone when patients develop intolerable side effects to morphine, as recommended by the American Society of Clinical Oncology 1, 5